Deadline Extended! Fierce Innovation Awards: Life Sciences Edition
Due to popular demand, the submission deadline has been extended to July 17, 2020 — enter today!
After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.
Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.
The deal, which is worth up to $160 million per molecule in milestones, comes as Junshi tries to pull off a $684 million IPO.